Test video series Daw

#accordion { max-width: 100%; height: auto; text-align: left; } section.accordion { padding-top: 2em; padding-bottom: 3em; } #accordion ul { text-align: left; } .transition, p, ul li icon:before, ul li icon:after { transition: all 0.3s; } #accordion .no-select, #accordion h2 { -webkit-tap-highlight-color: transparent; -webkit-touch-callout: none; user-select: none; } #accordion h1 { color: #286e50; margin-bottom: 30px; margin-top: 0; } #accordion h2 { color: #286e50; font-size: 3rem; font-weight: 700; line-height: 3.9rem; margin: 0; display: -webkit-box; display: -webkit-flex; display: -moz-box; display: -ms-flexbox; display: flex; -webkit-box-pack: justify; -webkit-justify-content: space-between; -moz-box-pack: justify; -ms-flex-pack: justify; justify-content: space-between; -webkit-box-align: center; -webkit-align-items: center; -moz-box-align: center; -ms-flex-align: center; align-items: center; -webkit-flex-wrap: wrap; -ms-flex-wrap: wrap; flex-wrap: wrap; } #accordion h3 { color: #296E4F; font-family: 'hm_light', sans-serif; font-size: 3rem; font-weight: 700; line-height: 3.9rem; text-align: left; padding: 15px 15px 15px; text-transform: none; font-weight: 300; letter-spacing: 1px; display: block; margin: 0; cursor: pointer; transition: .2s; border: #296E4F solid 2px; box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1); } #accordion p { color: #333; text-align: left; font-size: 14px; line-height: 1.45; position: relative; overflow: hidden; max-height: auto; will-change: max-height; contain: layout; display: inline-block; opacity: 1; transform: translate(0, 0); margin-top: 5px; margin-bottom: 15px; padding: 0 50px 0 15px; transition: .3s opacity, .6s max-height; hyphens: auto; z-index: 2; } #accordion ul { list-style: none; perspective: 900; padding: 0; margin: 0; } #accordion ul li { position: relative; overflow: hidden; padding: 0; margin: 0; /*padding-bottom: 4px;*/ /*padding-top: 18px;*/ background: #fff; -webkit-tap-highlight-color: transparent; } #accordion ul li + li { margin-top: 15px; } #accordion ul li:last-of-type { padding-bottom: 0; } #accordion ul li icon { position: absolute; transform: translate(-6px, 0); margin-top: 28px; right: 25px; } #accordion ul li icon:before, ul li icon:after { content: ""; position: absolute; background-color: #286e50; width: 3px; height: 9px; } #accordion ul li icon:before { transform: translate(-2px, 0) rotate(45deg); } #accordion ul li icon:after { transform: translate(2px, 0) rotate(-45deg); } #accordion ul li input[type=checkbox] { position: absolute; cursor: pointer; width: 100%; height: 100%; z-index: 1; opacity: 0; touch-action: manipulation; } #accordion ul li input[type=checkbox]:checked ~ h2 { color: #286e50; } #accordion ul li input[type=checkbox]:checked ~ p { /*margin-top: 0;*/ max-height: 0; transition: .3s; opacity: 0; /*transform: translate(0, 50%);*/ } #accordion ul li input[type=checkbox]:checked ~ icon:before { transform: translate(2px, 0) rotate(45deg); } #accordion ul li input[type=checkbox]:checked ~ icon:after { transform: translate(-2px, 0) rotate(-45deg); } #accordion ol { display: block; list-style-type: decimal; margin-block-start: 1em; margin-block-end: 1em; margin-inline-start: 0px; margin-inline-end: 0px; padding-inline-start: 40px; } #accordion .button { background-color: #286e50; border: none; color: white; padding: 15px 32px; text-align: center; text-decoration: none; display: inline-block; font-size: 16px; } #accordion * { box-sizing: border-box; margin: 0; padding: 0; } #accordion a, a:visited, a:focus, a:active, a:link { text-decoration: none; outline: 0; } #accordion a { color: currentColor; transition: .2s ease-in-out; } #accordion h1, h2, h3, h4 { margin: .3em 0; } #accordion ul { padding: 0; list-style: none; } #accordion img { vertical-align: middle; height: auto; width: 100%; }

This virtual round table series focuses on dysphagia and the management of patients in need of lipid-lowering medications. The first three sessions of this video series are presented by Dr Yassir Javaid (Northamptonshire CCG, UK), Prof Nina Barnett (London North West University Healthcare NHS Trust, UK) and Mr Paresh Parmar (London North West Healthcare NHS Trust, UK) followed by session four, a faculty discussion on patient case study. 

Dysphagia is a life-threatening disorder that can be caused by a number of conditions, such as stroke, neurological disorders and tumours. By participating in this series, you will gain further insight into the diagnosis of dysphagia, medication adherence, the importance of lipid management and individualising your treatment approach. The renowned faculty will also present and discuss a real-life clinical study.

Why Choose Atorvastatin Oral Suspension?

In this section, we explore the effectiveness of Atorvastatin Oral Suspension, its effortless administration, and its potential to enhance patient compliance. We underscore the crucial role of liquid medicine in meeting specific patient requirements. Delve deeper into the world of liquid medicine and its transformative impact on statin therapy delivery, ultimately improving patient care and outcomes for those experiencing dysphagia.

 

• NEW - Delve Deeper Into the World of Liquid Medicines

  
  
  Managing Dysphagia
  
  Dysphagia, or difficulty swallowing, is a common and often debilitating condition that affects individuals of all ages. It can result from various causes, including neurological disorders, structural anatomical abnormalities, or muscular dysfunction. Dysphagia can have significant consequences on a person's quality of life, nutritional status and overall health. Therefore, it is crucial to increase awareness and understanding of this condition to ensure timely diagnosis, appropriate management and improved patient outcomes. When addressing the specific swallowing needs of individual patients, opting for liquid medications can be a valuable strategy to mitigate potential risks. However, it is crucial to engage with clinicians who have expertise in dysphagia in order to ensure a comprehensive approach to selecting and administering liquid medicines that align with the person's swallowing capabilities and requirements.
  
  Dysphagia is a prevalent complication affecting a significant proportion of individuals. Among patients who have suffered a stroke, up to two-thirds experience dysphagia1,highlighting its high occurrence in this population. Additionally, up to approximately 60% of individuals with dementia also face the challenge of dysphagia1. It has been reported that between 10 and 40% of all adult’s experience difficulty in swallowing solid tablets2. In addition, dysphagia has a high prevalence among the elderly3. Management strategies for dysphagia may include dietary modifications, swallowing exercises and the use of assistive devices4. In some cases, liquid medications or alternate formulations are prescribed to address swallowing difficulties and ensure medication adherence.
  
  Atorvastatin Oral Suspension
  
  Atorvastatin oral suspension, which is a liquid formulation of the medication Atorvastatin, offers specific advantages over its solid dosage form counterparts. Atorvastatin is commonly prescribed to lower cholesterol levels and reduce the risk of cardiovascular events. With a liquid form of Atorvastatin, it may be more convenient for patients who have difficulty swallowing tablets. Moreover, Atorvastatin oral suspension allows for flexible dosing options. Physicians can easily adjust the dosage based on individual patient needs, making it particularly useful in cases where precise dosing is required, such as paediatric patients or those with specific dosage requirements. Rosemont Pharmaceuticals specialises in liquid medicines, specifically designed to meet the needs of patients who face challenges with swallowing solid medications or require precise dosing. By providing a liquid option, HCPs can support patients who struggle with swallowing tablets to receive their optimum therapy, enhancing both comfort and treatment adherence. Additionally, Rosemont's dedication to maintaining quality and consistency in their liquid formulations provides assurance to HCPs that patients are receiving the intended dose.
  
  Enhancing Outcomes with Liquid Statin Medications
  
  Improving cardiovascular outcomes necessitates addressing non-adherence to statin therapy and one crucial approach is the provision of liquid statin medications. The effectiveness of statin treatment relies on adherence to the prescribed regimen5. Unfortunately, adherence to statin therapy is frequently below optimal levels, resulting in inadequate reduction of LDL-C levels5. Non-adherence to treatment can stem from various factors and these reasons are often specific to each patient's circumstances and personal considerations6. Statin non-adherence poses a significant clinical burden6. For individuals who have difficulty swallowing solid tablets, their treatment adherence and therapeutic outcomes can be compromised7. This often leads people with dysphagia to resort to crushing tablets, which carries the risk of adverse drug reactions7. It is important to note that the Royal Pharmaceutical Society advises that if the formulation of a medicine is manipulated, then the product will then be classed as unlicensed8. However, the use of liquid medicines offers a solution to mitigate these risks. Liquid formulations may provide a more suitable and easier-to-swallow option for individuals with dysphagia, ensuring that they can take their medication without the challenges associated with solid tablets9. By addressing the issue of non-adherence through the availability of liquid medications, the clinical burden of statin non-adherence can be reduced, leading to improved outcomes and a decreased risk of stroke, major cardiac events and mortality10.
  
  Addressing statin non-adherence through the availability of liquid statin medications is essential to enhance cardiovascular outcomes. Atorvastatin was the leading dispensed statin in England in 202211. It is now available in a licensed liquid format. By raising awareness, promoting the use of liquid medications and addressing non-adherence, healthcare professionals can significantly improve patient care and outcomes for individuals affected by dysphagia and who require statin therapy.
  
  To access additional patient management resources, download the helpful infographic here
  
  References
  
  1. Royal college of speech and language therapy (2018) Guidance on the management of dysphagia in care homes.
  2. Forough et al. 2018, A spoonful of sugar helps the medicine go down? A review of strategies for making pills easier to swallow, Patient Prefer Adherence 2018 Jul 26;12:1337-1346.
  3. National Health Service. Swallowing problems (dysphagia). NHS. Retrieved July 11, 2023, from https://www.nhs.uk/conditions/swallowing-problems-dysphagia/
  4. National Health Service. Statins. NHS. Retrieved July 10, 2023, from https://www.nhs.uk/conditions/statins/Drexel et al. 2020.
  5. García-Fernández-Bravo et al. 2022. Undertreatment or Overtreatment With Statins: Where Are We? Front Cardiovasc Med. 2022; 9: 808712.
  6. Howell et al. 2004, Understanding Statin Non-Adherence: Knowing Which Perceptions and Experiences Matter to Different Patients, PLoS One. 2016; 11(1): e0146272.
  7. Strachan & Greener 2005, Medication-related swallowing difficulties may be more common than we realise, Pharmacy in Practice, 2005/11/01.
  8. RPS Pharmaceutical Issues when crushing, opening or splitting oral dosage forms. June 2011.
  9. Greenwall R. Medicine Management. Medicines management and older people – a guide for healthcare professionals. Aug 2017.
  10. Lansberg et al.  2018, Nonadherence to statins: individualized intervention strategies outside the pill box, Vasc Health Risk Manag. 2018; 14: 91–102.
  11. Statista. Leading chemical substances dispensed in England in 2021. Available from: https://www.statista.com/statistics

ROS000011-005 August/2023